---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-038073"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:12:43.210263+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Milestone reports FY2022 operating loss of $58.4M; NDA for etripamil on track for Q3 2023

## Summary
- Cash, equivalents, and short-term investments of $64.6M as of Dec 31, 2022; plus $50M from March 2023 private placement expected to fund into mid-2025.
- NDA submission for etripamil nasal spray in PSVT expected in Q3 2023; Phase 3 RAPID trial met primary endpoint (64.3% conversion vs 31.2% placebo).
- Entered $125M strategic financing with RTW Investments: $50M convertible notes and $75M synthetic royalty commitment post-FDA approval.
- Seth H.Z. Fischer appointed to Board of Directors effective March 21, 2023; brings commercial expertise from Johnson & Johnson and Vivus.
- Full year 2022 operating loss of $58.4M vs $42.9M in 2021; R&D expense $39.8M, G&A $15.7M, commercial $9.1M.

## SEC filing metadata
- accession: 0001104659-23-038073
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465923038073/0001104659-23-038073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465923038073/tm2310783d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-038073
- JSON: https://secwatch.observer/filing/0001104659-23-038073.json
- Plain text: https://secwatch.observer/filing/0001104659-23-038073.txt

## Key facts
- Earnings Releases
  Milestone Pharmaceuticals Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.
  - Period: fourth quarter and fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 29, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022, which also provided a clinical and corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1408443/000110465923038073/0001104659-23-038073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.